KAMEOKA Yoshihiro



Graduate School of Medicine  Doctorial Course in Medicine  Oncoregulatory Medicine  Department of Hematology,Nephrology,and Rheumatology

Research Fields, Keywords

malignant lymphoma

Graduating School 【 display / non-display


    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display


    Akita University  Graduate School,Division of Medicine  Doctor's Course  Completed

Campus Career 【 display / non-display

  • 2020.09

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Oncoregulatory Medicine   Department of Hematology,Nephrology,and Rheumatology   Associate Professor  

  • 2015.09

    Akita University   Hospital   Pharmaceutical Management Center   Associate Professor  

Research Field (grants-in-aid-for-scientific-research classification) 【 display / non-display

  • Hematology

Qualification acquired 【 display / non-display

  • Doctor


Thesis for a degree 【 display / non-display

  • Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma

    Kameoka Y, Tagawa H, Tsuzuki S, Karnan S, Ota A, Suguro M, Suzuki R, Yamaguchi M, Morishima Y, Nakamura S, Seto M 


    Domestic Co-author

Published Papers 【 display / non-display

  • Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis

    FUJISHIMA Masumi, TAKAHASHI Naoto, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro

    Rinsho Ketsueki ( The Japanese Society of Hematology )  58 ( 7 ) 743 - 748   2017

    <p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>

    DOI CiNii

  • TAFRO Syndrome with Bilateral Adrenal Hemorrhage

    Ito Fumiko, Kameoka Yoshihiro, Nara Miho, Ubukawa Kumi, Fujishima Masumi, Yoshioka Tomoko, Fujishima Naohito, Takahashi Naoto

    Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine )  106 ( 2 ) 288 - 294   2017

    DOI CiNii